while in the rapidly evolving area of oncology research, correct and productive mutation screening is essential for building targeted therapies. The KRAS products and services System plays a pivotal purpose On this landscape by presenting in depth solutions for KRAS mutation profiling and analysis. KRAS mutations, found in close to 95% of RAS-relat